Is CSPC Pharma (1093) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 7.7% / 30% | 4.8% / 30% | 0.0% / 5% | ✓ HALAL |
| DJIM | 0.5% / 33% | 7.7% / 33% | 4.8% / 33% | 0.0% / 5% | ✓ HALAL |
| MSCI | 1.1% / 33% | 18.6% / 33% | 11.6% / 33% | 0.0% / 5% | ✓ HALAL |
| S&P | 0.5% / 33% | 7.7% / 33% | 4.8% / 33% | 0.0% / 5% | ✓ HALAL |
| FTSE | 1.1% / 33% | 18.6% / 33% | 11.6% / 50% | 0.0% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 65.6% | |
| Operating Margin | 8.4% | |
| Net Margin | 14.9% | |
| Return on Equity (ROE) | 11.3% | |
| Return on Assets (ROA) | 5.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $4.5B |
| Free Cash Flow | $1.9B |
| Total Debt | $507M |
| Debt-to-Equity | 1.9 |
| Current Ratio | 2.2 |
| Total Assets | $44.4B |
Price & Trading
| Last Close | HKD 8.16 |
| 50-Day MA | HKD 9.57 |
| 200-Day MA | HKD 9.06 |
| Avg Volume | 106.8M |
| Beta | 0.9 |
|
52-Week Range
HKD 4.63
| |
About CSPC Pharma (1093)
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CSPC Pharma (1093) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CSPC Pharma is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CSPC Pharma's debt ratio?
CSPC Pharma's debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are CSPC Pharma's key financial metrics?
CSPC Pharma has a market capitalization of $106.1B, trailing P/E ratio of 24.4, and revenue of $29.0B. The company maintains a gross margin of 65.6% and a net margin of 14.9%. Return on equity stands at 11.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.